drugset / Trial / NCT02570022

Liposomal Bupivacaine in Total Shoulder Arthroplasty

NCT02570022 ↗

Phase 4 Completed 57 enrolled Henry Ford Health System
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, single blinded, standard of care controlled clinical trial. All adult patients over eighteen desiring shoulder arthroplasty will be eligible. The study compares pain control and opioid consumption in patients undergoing shoulder arthroplasty between patients receiving liposomal bupivacaine and those who underwent a preoperative inter-scalene nerve block.

Timeline

Start
2014-10
Primary completion
2016-05
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 133 mg Other
Comparator Ropivacaine Other / unclassified — Other

Indications

No indication recorded.